Mexedrone

Mexedrone (4-methoxymethcathinone, 4-MMC-methoxy, mexedrine) is a synthetic stimulant of the cathinone chemical class, structurally derived from mephedrone (4-MMC) through replacement of the 4-methyl group with a 4-methoxy group. This single-atom substitution produces a compound with a meaningfully different pharmacological profile: where mephedrone is a potent dopamine and norepinephrine releasing agent with significant entactogenic serotonergic activity, mexedrone is primarily a serotonin releasing agent and monoamine reuptake inhibitor — substantially weaker in its overall potency and with a different qualitative character.

Mexedrone's serotonin-dominant pharmacology (it is approximately 10–20 times weaker than mephedrone in dopamine/noradrenaline reuptake inhibition, while retaining serotonin releasing properties) means the subjective experience is relatively mild by cathinone standards: modest mood lift, mild empathogenic qualities, reduced anxiety, and limited stimulation. Users often describe it as a gentle entactogen with a softer hedonic impact than mephedrone or MDMA analogs, and with correspondingly less compulsive character than potently dopaminergic cathinones.

Despite its milder profile, mexedrone carries the fundamental risks of serotonergic substances: serotonin syndrome risk in combination with MAOIs and other serotonergic agents, and the potential for serotonergic neurotoxicity with heavy repeated use. The serotonin-dominant mechanism also means mexedrone produces typical serotonin-mediated effects including bruxism (jaw clenching), hyperthermia risk in active environments, and the serotonin depletion comedown.

Mexedrone is frequently discussed in the context of combining with other substances to add an entactogenic dimension to a stimulant experience — but this combination use amplifies the serotonergic risk and is not advisable. Its milder subjective profile makes its inherent pharmacological risks easier to underestimate.